Table 2 Characteristics of the nine patients with recurrences
No. | Menopausal | CA-125/ CA 19–9 | Primary surgery | FIGO stage | Coexisting EMS / ED | Adjuvant therapy | Min. / IEC | RFI (mo) | Recurrence | F/U (mo) | Current status | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Path | Extent | Staging | Sites | Histology | Treatment | ||||||||||
#1 | N | 217.6 / NA | Lam. | Radical | Yes | IC | Y / N | Chemo. | N / Y | 68 | Rectum & liver | EOC, twice | RCRS at 1st, chemotherapy at 2nd | 80 | AWD |
#2 | N | 291.0 / NA | Lam. | Radical | Yes | IC | Y / N | Chemo. | N / N | 6 | Pelvic | BOT | RCRS | 35 | NED |
#3 | N | 1037.0 / NA | Lam. | Radical | Yes | IIIB | N / N | Chemo. | N / Y | 111 | Pelvic | BOT | RCRS | 113 | NED |
#4 | N | 164.3 / NA | Lam. | Radical | No | IC | Y / N | No | N / Y | 23 | Contralateral ovary & rectum | EBOT, twice | RCRS at 1st, RCRS and chemotherapy at 2nd | 67 | NED |
#5 | N | NA / NA | Lap. | USO | Yes | IC | N / Y | No | N / N | 137 | Contralateral ovary | EBOT | TAH + USO | 147 | NED |
#6 | N | NA / NA | Lam. | USO | No | IC | N / Y | Chemo. | N / N | 102 | Contralateral ovary | EBOT | Lap. UC | 126 | NED |
#7 | N | 52.6 / NA | Lam. | UC | No | IC | Y / N | Chemo. | N / N | 8 | Ipsilateral ovary and LN | EOC, three times | CRS and chemotherapy at 1st, RCRS and chemotherapy at 2nd | 48 | AWD |
#8 | N | 21.2 / 12.4 | Lap. | UC | No | IA | N / N | No | N / N | 25 | Ipsilateral ovary | EBOT | Lap. USO | 31 | NED |
#9 | N | 21.7 / 7.5 | Lap. | UC | No | IC | N / Y | No | N / N | 18 | Bilateral ovaries | EOC | Staging | 50 | NED |